Berno Maaswinkel (born in 1972) is an experienced pharma executive. Being a member of the country leadership teams he has built a strong track record in building and leading result oriented teams with great passion for ophthalmology in the complex and strongly regulated area of drug development.
Berno has lead teams in the Netherlands, Belgium and Luxembourg working on different eye diseases like dry eye, anti infectives, glaucoma, macula degeneration and recently launched the first gene therapy in the Netherlands. Berno has build a network in the international ophtalmology environment and collaborated with different project teams in Europe to bring a solution to patients with an eye disease.
“I have seen many times what loosing sight means for patients. Sometimes at a very young age. That motivates me to give all of my energy to help build ASTHERNA and bring our promising and unique RNA therapies to the market”.
